Lilly EA, Cameron JE, Shetty KV, Leigh JE, Hager S, McNulty KM, Cheeks C,
Hagensee ME, Fidel PL Jr. Lack of evidence for local immune activity in oral
hairy leukoplakia and oral wart lesions. Oral Microbiol Immunol. 2005 Jun;20(3):154-62.
Kissinger PJ, Dumestre J, Clark RA, Wenthold L, Mohammed H, Hagensee ME,
Martin DH. Vaginal swabs versus lavage for detection of Trichomonas vaginalis
and bacterial vaginosis among HIV-positive women. Sex Transm Dis. 2005
Apr;32(4):227-30.
Chaturvedi AK, Dumestre J, Gaffga AM, Mire KM, Clark RA, Braly PS, Dunlap K,
Beckel TE, Hammons AF, Kissinger PJ, Hagensee ME. Prevalence of human
papillomavirus genotypes in women from three clinical settings. J Med Virol.
2005 Jan;75(1):105-13.
Thompson DL, Douglas JM Jr, Foster M, Hagensee ME, Diguiseppi C, Baron AE,
Cameron JE, Spencer TC, Zenilman J, Malotte CK, Bolan G, Kamb ML, Peterman TA;
Project RESPECT Study Group. Seroepidemiology of infection with human
papillomavirus 16, in men and women attending sexually transmitted disease
clinics in the United States. J Infect Dis. 2004 Nov 1;190(9):1563-74.
Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection
and disease in HIV-infected individuals. Am J Med Sci. 2004 Jul;328(1):57-63.
Chaturvedi AK, Brinkman JA, Gaffga AM, Dumestre J, Clark RA, Braly PS,
Dunlap K, Kissinger PJ, Hagensee ME. Distribution of human papillomavirus type
16 variants in human immunodeficiency virus type 1-positive and -negative
women. J Gen Virol. 2004 May;85(Pt 5):1237-41.
Brinkman JA, Rahmani MZ, Jones WE, Chaturvedi AK, Hagensee ME. Optimization
of PCR based detection of human papillomavirus DNA from urine specimens. J Clin
Virol. 2004 Apr;29(4):230-40.
Palmisano ME, Gaffga AM, Daigle J, Brinkman J, Mire K, Lenczyk K, Martin DH,
Hagensee ME. Detection of human papillomavirus DNA in self-administered vaginal
swabs as compared to cervical swabs. Int J STD AIDS. 2003 Aug;14(8):560-7.
Cameron JE, Snowhite IV, Chaturvedi AK, Hagensee ME. Human
papillomavirus-specific antibody status in oral fluids modestly reflects serum
status in human immunodeficiency virus-positive individuals. Clin Diagn Lab
Immunol. 2003 May;10(3):431-8.
Brinkman JA, Jones WE, Gaffga AM, Sanders JA, Chaturvedi AK, Slavinsky III
J, Clayton JL, Dumestre J, Hagensee ME. Detection of human papillomavirus DNA
in urine specimens from human immunodeficiency virus-positive women. J Clin
Microbiol. 2002 Sep;40(9):3155-61.
Snowhite IV, Jones WE, Dumestre J, Dunlap K, Braly PS, Hagensee ME. Comparative
analysis of methods for collection and measurement of cytokines and
immunoglobulins in cervical and vaginal secretions of HIV and HPV infected
women. J Immunol Methods. 2002 May 1;263(1-2):85-95.
Slavinsky J 3rd, Kissinger P, Burger L, Boley A, DiCarlo RP, Hagensee ME. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS. 2001 Aug;12(8):516-23.
Hagensee ME. Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment. Curr Infect Dis Rep. 2000 Feb;2(1):18-24.
Hagensee, Michael E., Yaegashi, N., and Galloway, Denise A. Self-assembly of Human Papillomavirus type 1 capsids by expression of the L1 protein alone or by co-expression of the L1 and L2 capsid proteins. J. Virology 67:315-322, (1993).
Carter, Joseph J., Hagensee, Michael, Taflin, Mary C., Lee, Shu K., Koutsky, Laura A., and Galloway, Denise A. HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology 195: 456-462 (1993).
Michael E. Hagensee and Denise A. Galloway. Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Report 4:121-123 (1993).
Carter, Joseph J., Michael E. Hagensee, Shu K. Lee, Barbara McKnight, Laura A. Koutsky, and Denise A. Galloway. Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology, 199:284-291 (1994).
Hagensee, M., N. Olson, T. Baker, and D. Galloway. Three dimensional structural analysis of vaccinia virus-produced HPV-1 capsids. J. Virology. 68: 4503-4505 (1994).
Hagensee, Michael E., Joseph J. Carter, Greg P. Wipf, and Denise A. Galloway. Serological and mucosal response in mice to vaccinia-virus produced HPV-1 capsids. Virology 206:174-182 (1995).
Carter, Joseph J., Wipf, Greg, Hagensee, Michael E., McKnight, Barbara, Habell, Lauri, Lee, Shu K., Kuypers, J., Kiviat, N., Daling, Janet, Koutsky, Laura A., Watts, D. Heather, Holmes, King K., and Denise A. Galloway. Use of Human Papillomavirus type 6 capsids produced by recombinant vaccinia viruses in ELISA to detect antibodies in people with genital warts. J. Infectious Disease 172:11-18 (1995).
Daling, Janet R., Madeleine, Margaret M., McKnight, Barbara, Carter, Joseph J., Hagensee, Michael E., Schwartz, Stephen M., Beckmann, Anna Marie, Mandelson, Margaret T., and Galloway, Denise A. The relationship of Human Papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior Herpes Simplex-2 infection. Cancer Epidemiology Biomarkers and Prevention. 5:541-548 (1996).
Hagensee, M. E., N. Kiviat, et al. (1997). "Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men." J Infect Dis 176(3): 625-31.
Madeleine, M. M., J. R. Daling, et al. (1997). "Cofactors with human papillomavirus in a population-based study of vulvar cancer." J Natl Cancer Inst 89(20): 1516-23.
Hagensee, M. E., J. Slavinsky, 3rd, et al. (1999). "Seroprevalence of human papillomavirus type 16 in pregnant women." Obstet Gynecol 94(5 Pt 1): 653-8.
Hagensee, M. E. (2000). "Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment." Curr Infect Dis Rep 2(1): 18-24.
Hagensee, M. E., L. A. Koutsky, et al. (2000). "Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions." J Infect Dis 181(4): 1234-9.
Slavinsky, J., 3rd, P. Kissinger, L.Burger, A. Boley, RP DiCarlo, ME Hagensee. (2001). "Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients." Int J STD AIDS 12(8): 516-23.